This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

TIDES: Oligonucleotide & Peptide Therapeutics Content Hub
24/7 Access
Digital & In-Person
Menu

Jesper Lau, PhD
Vice President, Protein and Peptide Chemistry at Novo Nordisk A/S
Speaker

Agenda Sessions

  • Discovery and Development of Semaglutide – The First Orally Available GLP-1 Peptide for Treatment of Type 2 Diabetes

    On Demand - For Members
    View Session

At this event

Prev
Next
Rodney Lax, Ph.D.
Business Development Consultant
Enzytag BV

See Jesper at TIDES: Oligonucleotide & Peptide Therapeutics Content Hub